ARTICLE | Clinical News
3DP-4815: Began Phase I study
January 24, 2000 8:00 AM UTC
3-Dimensional Pharmaceuticals Inc., Exton, Penn. Product: 3DP-4815 Business: Cardiovascular Therapeutic category: Thrombolysis/Thrombosis Target: Thrombin Description: Oral thrombin inhibitor anticoag...